Centers for Innovation in Advanced Development & Manufacturing
-or-
CIADM

Mike Angelastro
Project Officer
Division of Manufacturing, Facilities & Engineering

BARDA Industry Day
Contracting for Countermeasures
October 17, 2011
Key Initiatives

1. Expand Product Pipeline through Concept Acceleration Program (CAP) at NIAID

2. Establish a Strategic Investment (SI) Fund to increase investments in commercial ventures with multi-use potential (BARDA & NIAID)

3. Establish Centers for Innovation in Advanced Development and Manufacturing (BARDA)

4. Optimize influenza vaccine development and manufacturing (BARDA, NIAID, FDA, CDC)

5. Investment in upgrading science capacity at FDA
## Outreach to Potential Performers

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEP 15, 2010</td>
<td>‘DRAFT’ Solicitation [DRAFT-AMCG-10-39]</td>
</tr>
<tr>
<td>OCT 5-8, 2010</td>
<td>One-on-one Meetings</td>
</tr>
<tr>
<td>OCT 29, 2010</td>
<td>Questions/Comments Received</td>
</tr>
<tr>
<td>JAN 25, 2011</td>
<td>Responses Posted (~242)</td>
</tr>
<tr>
<td>MAR 02, 2011</td>
<td>Synopsis Posted [11-100-SOL-00011]</td>
</tr>
<tr>
<td>MAR 30, 2011</td>
<td>Solicitation Issued</td>
</tr>
<tr>
<td>APR 15, 2011</td>
<td>Round 1 Questions/Comments Received</td>
</tr>
<tr>
<td>APR 25, 2011</td>
<td>1st Pre-proposal Conference</td>
</tr>
<tr>
<td>MAY 05, 2011</td>
<td>Amendment #1 &amp; Round 1 Responses (~122) Posted</td>
</tr>
<tr>
<td>MAY 18, 2011</td>
<td>Round 2 Questions/Comments Received</td>
</tr>
<tr>
<td>JUN 01, 2011</td>
<td>2nd Pre-proposal Conference</td>
</tr>
<tr>
<td>JUN 06, 2011</td>
<td>Amendment #2 &amp; Round 2 Responses (~153) Posted</td>
</tr>
<tr>
<td>JUN 28, 2011</td>
<td>Round 3 Questions/Comments Received</td>
</tr>
<tr>
<td>JUN 28-29, 2011</td>
<td>One-on-one Communication Sessions</td>
</tr>
<tr>
<td>JUL 07, 2011</td>
<td>Amendment #3 &amp; Round 3 Responses (~22) Posted</td>
</tr>
<tr>
<td>JUL 13, 2011</td>
<td>Amendment #4 Posted</td>
</tr>
<tr>
<td>JUL 21, 2011</td>
<td>PROPOSALS DUE</td>
</tr>
</tbody>
</table>
Objectives of the RFP

- Establish public-private partnerships to construct/retrofit U.S.-based, commercial-scale, biopharmaceutical facilities that support advanced development and manufacturing of MCMs

- Provide core services, on a routine basis, for the advanced development and manufacturing of CBRN biopharmaceuticals supported by the U.S. Government

- Provide, in an emergency, necessary U.S.-based surge capacity to respond to an emerging infectious disease, pandemic influenza, and currently known or unknown threats

- Provide biopharmaceutical oriented workforce development through training programs aligned with current regulatory guidelines
The Buzzwords!

Sustainable, domestic-based medical countermeasure manufacturing capabilities require innovative solutions!

- Speedy
- Multi-product Facility
- Nimble / Adaptable
- Flexible Manufacturing
- Single-use / Disposables
Mandatory Elements for Offeror

1. FDA Licensure of a Biopharmaceutical Product within the Last Ten (10) Years

2. U.S. Biopharmaceutical Manufacturing commitment
   • Core services through the lifetime of the facility

3. Cost Sharing
   • USG / Contractor Minimums:
     49% / 51% of the total cost of new construction -and/or-
     75% / 25% of the total cost to retrofit an existing facility

4. Surge Manufacturing Capacity for Pandemic Influenza Vaccine Production & Other Threats
   • Minimum: 50 million finished doses within four (4) months of task order receipt

5. Training Commitment
   • Biopharmaceutical-oriented program provided in conjunction with an accredited U.S. academic institution or other reputable organization(s)
The Procurement Process Presses Forward

*Dates on this slide are tentative, of course.*

OCT 2011 – Competitive Range Determination
- After the technical and business evaluation of Offerors’ proposal(s), the Contracting Officer determines the competitive range

OCT/ NOV 2011 – Pre-Award Site Visits
- Pre-award site visits are conducted for those Offeror(s) in the competitive range

NOV 2011 to JAN 2012 – Discussions
- Negotiations will be conducted with all Offeror(s) in the competitive range

JAN/ FEB 2012 – Final Proposal Revisions (FPR):
- Upon completion of negotiations, the Offeror(s) will be requested to submit their FPR

MAR 2012 – FPR Evaluations:
- The FPRs are evaluated in the similar manner in which the original evaluations were conducted focusing on the areas within the proposal that were revised

MAR/ MAY 2012 – Source Selection:
- Upon final review of the FPR, the Source Selection Evaluation Board (SSEB) Chairperson with the Contracting Officer will brief the Source Selection Authority (SSA) who will make the final decision on this Source Selection